Literature DB >> 20732756

Preoperative chemoradiotherapy (CRT) followed by laparoscopic surgery for rectal cancer: predictors of the tumor response and the long-term oncologic outcomes.

Jong Hoon Lee1, Sung Hwan Kim, Jun-Gi Kim, Hyun Min Cho, Byoung Yong Shim.   

Abstract

PURPOSE: We have evaluated the predictors of a tumor response to chemoradiotherapy (CRT) and the long-term oncologic outcomes of preoperative CRT and laparoscopic surgery for patients who suffer from rectal cancer. METHODS AND MATERIALS: The study involved 274 patients with locally advanced rectal cancer and who had been treated with preoperative CRT and curative laparoscopic total mesorectal excision between January 2003 and January 2009. We assessed the long-term oncologic outcomes, in terms of recurrence and survival, of the treated patients.
RESULTS: Forty-two (15.3%) of the 274 patients had complete pathologic responses (pCR). The pre-CRT carcinoembryonic antigen level was the only significant predictor of a pCR on the multivariate analysis (p = 0.01). The overall survival at 5 years was 73.1%, with a mean survival period of 59.7 months (95% CI, 57.1-62.3). The disease-free survival at 5 years was 67.3% with a mean survival period of 54.7 months (95% CI, 51.7-57.8). The pCR group had a higher rate of overall survival at 5 years than did the non-pCR group, and the difference was significant (86.0% vs. 71.2%; hazard ratio = 0.87; 95% CI, 0.78-0.96; p = 0.03). The cumulative incidences of local and distant recurrences at 5 years were 5.8% and 28.3%, respectively. A total of 84.5% (234 of 274) of the patients had their anal sphincters preserved. Grade 3 or 4 acute and long-term toxic effects occurred in 22.2% and 8.4% of the patients, respectively.
CONCLUSION: Preoperative CRT and laparoscopic surgery seems safe and feasible with favorable long-term outcomes and a high rate of sphincter preservation for the patients with low-lying tumors of the rectum.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20732756     DOI: 10.1016/j.ijrobp.2010.05.019

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

1.  Induction FOLFOX followed by preoperative hyperfractionated radiotherapy plus bolus 5-fluorouracil in locally advanced rectal carcinoma: single arm phase I-II study.

Authors:  Engy M Aboelnaga; Mohamed A Daoud; Entesar I Eladl; Amir M Zaid
Journal:  Med Oncol       Date:  2015-03-07       Impact factor: 3.064

2.  Laparoscopic total mesorectal excision for extraperitoneal rectal cancer: long-term results of a 18-year single-centre experience.

Authors:  Riccardo Brachet Contul; Manuela Grivon; Massimiliano Fabozzi; Paolo Millo; Mario Junior Nardi; Stefania Aimonetto; Umberto Parini; Rosaldo Allieta
Journal:  J Gastrointest Surg       Date:  2014-01-18       Impact factor: 3.452

3.  Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation.

Authors:  Xabier García-Albéniz; Rosa Gallego; Ralf Dieter Hofheinz; Gloria Fernández-Esparrach; Juan Ramón Ayuso-Colella; Josep Antoni Bombí; Carles Conill; Miriam Cuatrecasas; Salvadora Delgado; Angels Ginés; Rosa Miquel; Mario Pagés; Estela Pineda; Verónica Pereira; Aarón Sosa; Oscar Reig; Iván Victoria; Luis Feliz; Antonio María de Lacy; Antoni Castells; Iris Burkholder; Andreas Hochhaus; Joan Maurel
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

4.  Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation.

Authors:  Ovidio Hernando-Requejo; Mercedes López; Antonio Cubillo; Almudena Rodriguez; Raquel Ciervide; Jeannette Valero; Emilio Sánchez; Mariola Garcia-Aranda; Jesus Rodriguez; Guillermo Potdevin; Carmen Rubio
Journal:  Strahlenther Onkol       Date:  2014-04-09       Impact factor: 3.621

5.  Relations of Changes in Serum Carcinoembryonic Antigen Levels before and after Neoadjuvant Chemoradiotherapy and after Surgery to Histologic Response and Outcomes in Patients with Locally Advanced Rectal Cancer.

Authors:  Gota Saito; Sotaro Sadahiro; Takashi Ogimi; Hiroshi Miyakita; Kazutake Okada; Akira Tanaka; Toshiyuki Suzuki
Journal:  Oncology       Date:  2017-12-22       Impact factor: 2.935

6.  Hypofractionated radiotherapy with tomotherapy for patients with hepatic oligometastases: retrospective analysis of two institutions.

Authors:  Jong Hoon Lee; Joo Hwan Lee; Hong Seok Jang; Hyo Chun Lee; Jung Won Lee; Dae Gyu Kang; Byoung Yong Shim; Bong-Hyeon Kye; Hyung Jin Kim; Hyeon-Min Cho; Young Jin Suh; Sung Hwan Kim
Journal:  Clin Exp Metastasis       Date:  2013-02-06       Impact factor: 5.150

7.  Pathologic response to neoadjuvant treatment in locally advanced rectal cancer and impact on outcome.

Authors:  Mahshid Jalilian; Sidney Davis; Mohammadreza Mohebbi; Bhuvana Sugamaran; Ian W Porter; Stephen Bell; Satish K Warrier; Roger Wale
Journal:  J Gastrointest Oncol       Date:  2016-08

8.  Preoperative elevation of carcinoembryonic antigen predicts poor tumor response and frequent distant recurrence for patients with rectal cancer who receive preoperative chemoradiotherapy and total mesorectal excision: a multi-institutional analysis in an Asian population.

Authors:  Jong Hoon Lee; Sung Hwan Kim; Hong Seok Jang; Hyuk Jun Chung; Seong Taek Oh; Doo Seok Lee; Jun-Gi Kim
Journal:  Int J Colorectal Dis       Date:  2012-12-04       Impact factor: 2.571

Review 9.  Treatment of locally advanced rectal cancer: controversies and questions.

Authors:  Atthaphorn Trakarnsanga; Suthinee Ithimakin; Martin R Weiser
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

10.  The impact of pathologic nodal status on survival following neoadjuvant chemoradiation for locally advanced rectal cancer.

Authors:  Jonathan M Hernandez; Whalen Clark; Jill Weber; William J Fulp; Lauren Lange; David Shibata
Journal:  Int J Colorectal Dis       Date:  2014-06-27       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.